Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –

ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of John Harlow as the Company’s Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion’s Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. 
  
"We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion’s growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John’s deep domain expertise in building and scaling commercial organizations, combined with his proven success in driving revenue and leading high-performance teams, will be instrumental as we accelerate the delivery of our innovative cardiovascular risk reduction therapies to patients worldwide. His leadership will help ensure that our therapies reach the people who need it most."

Read more at globenewswire.com